Scholars Central

OpinionPublished 31 Mar 2025

Integrating Targeted Therapy into the Management of Bone Sarcomas

Authors: Irises Ali

Orthopedic Oncology, University of Alabama at Birmingham Medical Center, USA

Journal of Orthopedic Oncology

Volume 11 · Issue 2 · Pages 1–2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Bone sarcomas, including osteosarcoma, Ewing sarcoma, and chondrosarcoma, represent a rare but aggressive group of malignancies primarily affecting children, adolescents, and young adults. Despite advances in multimodal treatments involving surgery and chemotherapy, long-term survival for patients with metastatic or recurrent disease remains poor. The emergence of targeted therapies has introduced new possibilities for improving patient outcomes through precision oncology. These therapies aim to disrupt specific molecular pathways implicated in sarcoma growth and progression. This article explores the current landscape of targeted therapy in bone sarcomas, highlights the integration of molecular profiling into clinical practice, and discusses the challenges and future directions in optimizing these therapies as part of a comprehensive management strategy.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Orthopedic Oncology
  • SubjectOncology & Cancer
  • SubjectOrthopaedics
  • BylineArticles whose byline prints “Irises Ali”